MX380123B - Metodo para preparar una composicion farmaceutica que comprende un derivado de quinolina o una sal del mismo. - Google Patents

Metodo para preparar una composicion farmaceutica que comprende un derivado de quinolina o una sal del mismo.

Info

Publication number
MX380123B
MX380123B MX2018008862A MX2018008862A MX380123B MX 380123 B MX380123 B MX 380123B MX 2018008862 A MX2018008862 A MX 2018008862A MX 2018008862 A MX2018008862 A MX 2018008862A MX 380123 B MX380123 B MX 380123B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
preparing
salt
quinoline derivative
preparation process
Prior art date
Application number
MX2018008862A
Other languages
English (en)
Other versions
MX2018008862A (es
Inventor
Chenyang Wang
Xinhua Zhang
Yun Lu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018008862A publication Critical patent/MX2018008862A/es
Publication of MX380123B publication Critical patent/MX380123B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para preparar una composición farmacéutica que comprende un derivado de quinolina o una de sus sales. De manera específica, la invención proporciona un método para preparar una composición farmacéutica que comprende una (R,E)-N-(4-(3-cloro-4-(piridin-2-ilmetoxi)fenilamino)-3-ciano-7-etoxiquinolin-6-il)-3-(1-metilpirrolidin-2-il)-propenamida o una de sus sales farmacéuticamente aceptables. El método comprende utilizar un agente humectante que comprenda al menos un solvente orgánico para una granulación por vía húmeda en un proceso de preparación de la composición farmacéutica. La composición farmacéutica preparada utilizando el método tiene una distribución uniforme de tamaños de grano durante el proceso de preparación y una propiedad de disolución rápida y uniforme.
MX2018008862A 2016-01-27 2017-01-23 Metodo para preparar una composicion farmaceutica que comprende un derivado de quinolina o una sal del mismo. MX380123B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610057228 2016-01-27
PCT/CN2017/072156 WO2017129088A1 (zh) 2016-01-27 2017-01-23 一种含有喹啉衍生物或其盐的药物组合物的制备方法

Publications (2)

Publication Number Publication Date
MX2018008862A MX2018008862A (es) 2018-09-07
MX380123B true MX380123B (es) 2025-03-11

Family

ID=59397365

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008862A MX380123B (es) 2016-01-27 2017-01-23 Metodo para preparar una composicion farmaceutica que comprende un derivado de quinolina o una sal del mismo.

Country Status (24)

Country Link
US (1) US10722469B2 (es)
EP (1) EP3378479B1 (es)
JP (1) JP6937308B2 (es)
KR (1) KR20180103090A (es)
CN (2) CN107405345A (es)
AU (1) AU2017211737B2 (es)
BR (1) BR112018014544A2 (es)
CA (1) CA3008701A1 (es)
CY (1) CY1123149T1 (es)
DK (1) DK3378479T3 (es)
ES (1) ES2811031T3 (es)
HK (1) HK1243357A1 (es)
HR (1) HRP20201155T1 (es)
HU (1) HUE050255T2 (es)
LT (1) LT3378479T (es)
MX (1) MX380123B (es)
PL (1) PL3378479T3 (es)
PT (1) PT3378479T (es)
RS (1) RS60747B1 (es)
RU (1) RU2735807C2 (es)
SI (1) SI3378479T1 (es)
SM (1) SMT202000388T1 (es)
TW (1) TWI720115B (es)
WO (1) WO2017129088A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3701948A4 (en) * 2017-10-24 2021-08-25 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION WITH QUINOLINE DERIVATIVE
CN109496150A (zh) * 2018-03-23 2019-03-19 无锡双良生物科技有限公司 一种药物组合物及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
CN101824029A (zh) 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102020639A (zh) 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
US20130150386A1 (en) * 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
CN103987700B (zh) * 2012-03-09 2016-08-31 江苏豪森药业集团有限公司 4-喹唑啉胺类衍生物及其用途
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
SG11201705924RA (en) * 2015-01-30 2017-08-30 Biomed Valley Discoveries Inc CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb>

Also Published As

Publication number Publication date
DK3378479T3 (da) 2020-08-03
AU2017211737B2 (en) 2022-04-28
HRP20201155T1 (hr) 2020-10-30
US10722469B2 (en) 2020-07-28
RU2018128416A (ru) 2020-02-27
HK1243357A1 (zh) 2018-07-13
EP3378479A4 (en) 2018-12-19
KR20180103090A (ko) 2018-09-18
EP3378479B1 (en) 2020-06-17
SI3378479T1 (sl) 2020-10-30
RU2735807C2 (ru) 2020-11-09
JP6937308B2 (ja) 2021-09-22
PT3378479T (pt) 2020-07-20
JP2019503373A (ja) 2019-02-07
US20190054025A1 (en) 2019-02-21
ES2811031T3 (es) 2021-03-10
RS60747B1 (sr) 2020-10-30
CA3008701A1 (en) 2017-08-03
CN108938586A (zh) 2018-12-07
AU2017211737A1 (en) 2018-08-02
LT3378479T (lt) 2020-09-10
CY1123149T1 (el) 2021-10-29
RU2018128416A3 (es) 2020-04-21
PL3378479T3 (pl) 2020-11-02
MX2018008862A (es) 2018-09-07
TW201726138A (zh) 2017-08-01
TWI720115B (zh) 2021-03-01
HUE050255T2 (hu) 2020-11-30
CN107405345A (zh) 2017-11-28
CN108938586B (zh) 2021-05-14
SMT202000388T1 (it) 2020-09-10
BR112018014544A2 (pt) 2018-12-11
EP3378479A1 (en) 2018-09-26
WO2017129088A1 (zh) 2017-08-03

Similar Documents

Publication Publication Date Title
MX2023000085A (es) Compuestos antiproliferativos y metodos para utilizarlos.
IL269586A (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
HUE059624T2 (hu) N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
WO2017048702A8 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
EP2883875A4 (en) N2, N4-BIS (4- (PIPERAZINE-1-YL) PHENYL) PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY UNINTENTIONAL SALT AND COMPOSITION THEREOF AS ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF CANCER
HUE061963T2 (hu) Karbamid-vegyületek és készítmények mint SMARCA2/BRM-ATPáz gátlók
SI3256109T1 (sl) Farmacevtski sestavki, ki obsegajo N-(3,5-dimetoksifenil)-N&#39;-(1-metiletil)-N-(3-(metil-1H-pirazol-4-il) kinoksalin-6-il)etan-1,2-diamin
EP3181559A4 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
DK4079734T3 (da) Triazolopyridazinderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning deraf og anvendelse deraf
CY1124490T1 (el) Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο
BR112017023225A2 (pt) inibidor de proteína cinase
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
JP2018530581A5 (es)
CL2019002808A1 (es) Métodos para prevenir o tratar enfermedades oftálmicas.
DK3689379T3 (da) Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
PH12019500326A1 (en) Combination of fxr agonists
DK3634968T3 (da) Heterocykliske forbindelser, der kan anvendes som antibakterielle midler, og fremgangsmåde til fremstilling heraf
CY1123149T1 (el) Μεθοδος για την παρασκευη φαρμακευτικης συνθεσης που περιλαμβανει παραγωγο κινολινης ή αλας αυτου
NZ724718A (en) Compositions and methods for treating neurodegenerative diseases
ZA202401526B (en) 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2- (homo)piperazine 1,3-benzothiazine-4-one hydrochlorides
AR059838A1 (es) Formulaciones para dosis estabilizantes de estatina